3Long JK. Agents for the treatment of multidrug-resistant grampositive endocarditis [ J ]. Curr Infect Dis Rep, 2005, 7 (4) : 245-250.
4Stevens DL, Dotter B, Madaras-KeUy K. A review of linezolid : the first oxazolidinone antibiotic [ J ]. Expert Rev Anti Infect Ther, 2004, 2( 1 ) : 51-59.
5Garazzino S, De Rosa FG, Bargiacchi O, et al. Haematological safety of long-term therapy with linezolid[ J]. Int J Antimicrob Agents, 2007, 29(4): 480-483.
6Jeol G, Hardman, Lee E. Limbird. Goodman & Gilmans. The pharmacological basis of therapeutics [ M ]. 10th ed. New York: MeGraw Hill, 2001:1260.
7Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy [ J]. Clin Infect Dis, 2002, 34(5) : 695-698.
8Nasraway SA,Shorr AF,Kuter DJ,et al.Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia:comparative analysis of linezolid and vancomycin use[J].Clin Infect Dis,2003,37:1609-1616.
9Centers for Disease Control and Prevention (CDC).Staphylococcus aureus resistant to vancomycin-United States[J].MMWR Morb Mortal Wkly Rep,2002,51:565-567.
10Falagas ME,Siempos Ⅱ,Vardakas KZ.Linezolid versus glycopeptide or bata-lactam for treatment of Gram-positive bacterial infections:meta-analysis of randomised controlled trials[J].Lancet Infect Dis,2008,8:53-66.
